




The relative strengths and weaknesses of Agios Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Agios Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Agios Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 318%, being 69% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	613,780
Cost of Goods Sold	1,397
Intangible Assets	0
Liabilities, Current	93,503
Liabilities, Non-Current	59,809
Other Assets	220,357
Other Compr. Net Income	-782
Other Expenses	0
Other Liabilities	17,608
Other Net Income	16,451
Other Revenues	94,387
Property and Equipment	24,320
Research and Development	341,324
Selling, General and Administrative Expense	114,145

Output Variable	Value in 1000 USD
Assets	858,457
Liabilities	170,920
Expenses	456,866
Revenues	94,387
Stockholders Equity	687,537
Net Income	-346,028
Comprehensive Net Income	-346,419
BaseVar	798,932
ECR before LimitedLiability	224%
Economic Capital Ratio	318%